{"id":675492,"date":"2023-11-06T18:18:01","date_gmt":"2023-11-06T18:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=675492"},"modified":"2023-11-06T18:18:01","modified_gmt":"2023-11-06T18:18:01","slug":"obesity-pipeline-clinical-trials-key-companies-aardvark-adocia-agentix-agex-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/obesity-pipeline-clinical-trials-key-companies-aardvark-adocia-agentix-agex-therapeutics_675492.html","title":{"rendered":"Obesity Pipeline | Clinical Trials, Key Companies &#8211; Aardvark, Adocia, Agentix AgeX Therapeutics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Obesity Pipeline | Clinical Trials, Key Companies - Aardvark, Adocia, Agentix AgeX Therapeutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Obesity Pipeline | Clinical Trials, Key Companies - Aardvark, Adocia, Agentix AgeX Therapeutics\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cObesity Pipeline Insight, 2023,\u201d report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/obesity-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Obesity Pipeline Insight, 2023<\/a><\/strong>,&rdquo; report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from the Obesity Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Key Companies working in Obesity pipeline include Aardvark, Adocia, Agentix AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group AstraZeneca, and many others.<\/li>\n<li>The Key Therapies working in Obesity pipeline include Semaglutide, Tirzepatide, Tesomet, RZL-012, EMP16, ZP 8396, and many others&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Learn more about the key trends and developments driving the market growth @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/obesity-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Obesity Pipeline&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Obesity Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Obesity is recognized as a chronic or noncommunicable disease, a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity or body fatness which can manifest metabolically and not just concerning the size of the body. Unwanted body weight gain leading to obesity and overweight has become the main driver of the global rise in non-communicable diseases; therefore, it is considered a noncommunicable disease. Because of the psychological and social stigma associated with being overweight and obese, those affected are also vulnerable to discrimination in their personal and work lives, low self-esteem, and depression. Childhood obesity results in the same comorbidities as obesity, with premature onset or greater likelihood in adulthood. The medical and psychological sequel of obesity contributes to a major threat to the socioeconomic healthcare burden, which is striking.<\/p>\n<p style=\"text-align: justify;\"><strong>Obesity Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 100+ key companies that are developing therapies for Obesity. The Obesity companies which have their Obesity drug candidates in the most advanced stage, i.e. Phase III include, Novo Nordisk.<\/p>\n<p style=\"text-align: justify;\"><strong>Phases of Obesity Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s report covers around 130+ Obesity products under different phases of clinical development like<\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Obesity Products have been categorized under various Molecule types such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Product Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Obesity Drugs have been categorized under various product types like Mono, Combination and Mono\/Combination.<\/p>\n<p style=\"text-align: justify;\"><strong>Obesity Key Companies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novo Nordisk<\/li>\n<li>Eli Lilly and Company<\/li>\n<li>Eurofarma Laboratorios S.A.&nbsp;<\/li>\n<li>And many others&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Obesity Key Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Semaglutide oral<\/li>\n<li>Tirzepatide<\/li>\n<li>Sibutramine\/Topiramate&nbsp;<\/li>\n<li>And many others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major market share @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/obesity-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\"> Obesity Pipeline Report&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table border=\"0\" cellpadding=\"0\">\n<colgroup>\n<col width=\"73\" \/>\n<col width=\"554\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p>1.<\/p>\n<\/td>\n<td>\n<p>Obesity Market Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2.<\/p>\n<\/td>\n<td>\n<p>Obesity Market Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3.<\/p>\n<\/td>\n<td>\n<p>Obesity Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4.<\/p>\n<\/td>\n<td>\n<p>Obesity Market Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5.<\/p>\n<\/td>\n<td>\n<p>Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.<\/p>\n<\/td>\n<td>\n<p>Obesity Treatment and Management<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.<\/p>\n<\/td>\n<td>\n<p>Obesity Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8.<\/p>\n<\/td>\n<td>\n<p>Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10.<\/p>\n<\/td>\n<td>\n<p>Obesity Emerging Drugs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12.<\/p>\n<\/td>\n<td>\n<p>Obesity Market Outlook<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13.<\/p>\n<\/td>\n<td>\n<p>Potential of Current and Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14.<\/p>\n<\/td>\n<td>\n<p>KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15.<\/p>\n<\/td>\n<td>\n<p>Obesity&nbsp; Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16.<\/p>\n<\/td>\n<td>\n<p>Obesity&nbsp; Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17.<\/p>\n<\/td>\n<td>\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18.<\/p>\n<\/td>\n<td>\n<p>SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19.<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20.<\/p>\n<\/td>\n<td>\n<p>DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>21.<\/p>\n<\/td>\n<td>\n<p>Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>22.<\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong>Learn more about the report offerings @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/obesity-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Obesity Pipeline&nbsp;<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=obesity-pipeline-clinical-trials-key-companies-aardvark-adocia-agentix-agex-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=obesity-pipeline-clinical-trials-key-companies-aardvark-adocia-agentix-agex-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cObesity Pipeline Insight, 2023,\u201d report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/obesity-pipeline-clinical-trials-key-companies-aardvark-adocia-agentix-agex-therapeutics_675492.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,403,404],"tags":[],"class_list":["post-675492","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=675492"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675492\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=675492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=675492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=675492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}